BioNTech SE (BNTX)
The company now
BioNTech SE is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Mainz, DE. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of EUR 2.9 billion and a loss of EUR 1.1 billion (its filed statements).
From its filings and filed figures; the desk's account of it is not written yet.
Where the revenue comes from
fiscal 2025, as filedRevenue by product, fiscal 2025
| Product | Fiscal 2025 | Fiscal 2024 | Share of revenue |
|---|---|---|---|
| COVID19 Vaccine Revenues | €2.00B | €2.43B | 69.5% |
| Revenues From Out Licensing | €613M | n/a | 21.4% |
| Other Sales | €262M | €319M | 9.1% |
Revenue by region, fiscal 2025
| Region | Fiscal 2025 | Fiscal 2024 | Share of revenue |
|---|---|---|---|
| United States | €1.79B | €1.85B | 62.5% |
| Germany | €759M | €707M | 26.5% |
| Ireland | €305M | €178M | 10.6% |
| Rest of the World | €11.1M | €18.6M | under 1% |
As tagged in its annual report (Form 20-F/A, filed Jul 30, 2026 ↗), read from the SEC's financial statement data sets. The year before is the figure the record holds for the prior fiscal year.
The desk's written account of this company, its Past, Present and Future, is not on file yet.
How the company works
The desk has not read this company's annual report yet.
The record in brief
The desk has not written this company's report yet.